# CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

> **NCT07019363** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 1903 (estimated)

## Conditions studied

- Breast Cancer
- Adjuvant Therapy

## Interventions

- **DRUG:** Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- **DRUG:** Standard endocrine therapy combined with CDK4/6 Inhibitor

## Key facts

- **NCT ID:** NCT07019363
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2029-05-15
- **Final completion:** 2033-04-15
- **Target enrollment:** 1903 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07019363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07019363, "CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07019363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*